Keywords: Leo Pharma, Peplin, Mergers & acquisitions, dermatology
LEO Pharma to Acquire Peplin for $287.5 million
Article | 03 September 2009
Denmark-based Leo Pharma will acquire all outstanding securities of Peplin, a US firm with operations in Australia, for around $287.5 million ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
